Preoperative Antiviral Therapy and Long-Term Outcomes for Hepatitis B Virus-Related Hepatocellular Carcinoma After Curative Liver Resection: A Multicenter Analysis

References

• Llovet JM, Kelley RK, Villanueva A. et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. doi:10.1038/s41572-020-00240-3
   PubMed Web of Science ®Google Scholar
• Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156(2):477–491.e1.
   PubMed Web of Science ®Google Scholar
• Zaydfudim VM, Vachharajani N, Klintmalm GB, et al. Liver resection and transplantation for patients with hepatocellular carcinoma beyond Milan criteria. Ann Surg. 2016;264(4):650–658. doi:10.1097/SLA.0000000000001866
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Chen S, Li J, Wang D, Fung H, Wong LY, Zhao L. The hepatitis B epidemic in China should receive more attention. Lancet. 2018;391(10130):1572. doi:10.1016/S0140-6736(18)30499-9
   PubMed Web of Science ®Google Scholar
• Galle PR, Tovoli F, Foerster F, Wörns MA, Cucchetti A, Bolondi L. The treatment of intermediate stage tumours beyond TACE: from surgery to systemic therapy. J Hepatol. 2017;67(1):173–183.
   PubMed Web of Science ®Google Scholar
• Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11(9):525–535. doi:10.1038/nrclinonc.2014.122
   PubMed Web of Science ®Google Scholar
• Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013;58(1):98–107. doi:10.1002/hep.26180
   PubMed Web of Science ®Google Scholar
• Tang L, Covert E, Wilson E, Kottilil S. Chronic hepatitis B infection: a review. JAMA. 2018;319(17):1802–1813. doi:10.1001/jama.2018.3795
   PubMed Web of Science ®Google Scholar
• Hou JL, Zhao W, Lee C, et al. Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries. Clin Gastroenterol Hepatol. 2020;18(2):457–467.e21. doi:10.1016/j.cgh.2019.07.010
   PubMed Web of Science ®Google Scholar
• Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351(15):1521–1531. doi:10.1056/NEJMoa033364
   PubMed Web of Science ®Google Scholar
• Ohkubo K, Kato Y, Ichikawa T, et al. Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma. Cancer. 2002;94(10):2663–2668. doi:10.1002/cncr.10557
   PubMed Web of Science ®Google Scholar
• Zhang D, Feng D, Ren M, Bai Y, Liu Z, Wang H. Preoperative serum hepatitis B virus DNA was a risk factor for hepatocellular carcinoma recurrence after liver transplantation. Ann Med. 2022;54(1):2213–2221. doi:10.1080/07853890.2022.2107233
   PubMed Web of Science ®Google Scholar
• Kubo S, Hirohashi K, Tanaka H, et al. Effect of viral status on recurrence after liver resection for patients with hepatitis B virus-related hepatocellular carcinoma. Cancer. 2000;88(5):1016–1024. doi:10.1002/(SICI)1097-0142(20000301)88:5<1016::AID-CNCR10>3.0.CO;2-V
   PubMed Web of Science ®Google Scholar
• Huang G, Li PP, Lau WY, et al. Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels: a randomized controlled trial. Ann Surg. 2018;268(6):943–954. doi:10.1097/SLA.0000000000002727
   PubMed Web of Science ®Google Scholar
• Huang G, Lau WY, Wang ZG, et al. Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial. Ann Surg. 2015;261(1):56–66. doi:10.1097/SLA.0000000000000858
   PubMed Web of Science ®Google Scholar
• Yin J, Li N, Han Y, et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol. 2013;31(29):3647–3655. doi:10.1200/JCO.2012.48.5896
   PubMed Web of Science ®Google Scholar
• Li Z, Lei Z, Xia Y, et al. Association of preoperative antiviral treatment with incidences of microvascular invasion and early tumor recurrence in hepatitis B virus-related hepatocellular carcinoma. JAMA Surg. 2018;153(10):e182721. doi:10.1001/jamasurg.2018.2721
   PubMed Web of Science ®Google Scholar
• Li C, Li ZC, Ma L, et al. Perioperative antiviral therapy improves the prognosis of HBV DNA-negative patients with HBV-related hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2020;14(8):749–756. doi:10.1080/17474124.2020.1784727
   PubMed Web of Science ®Google Scholar
• Liu XF, Zhang T, Tang K, Sui LL, Xu G, Liu Q. Study of Preoperative Antiviral Treatment of Patients with HCC Negative for HBV-DNA. Anticancer Res. 2017;37(8):4701–4706. doi:10.21873/anticanres.11875
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-The ALBI grade. J Clin Oncol. 2015;33(6):550–558. doi:10.1200/JCO.2014.57.9151
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi:10.1016/j.jhep.2021.11.018
   PubMed Web of Science ®Google Scholar
• Pang YY, Belghiti J, Clavien P-A. The Brisbane 2000 terminology of liver anatomy and resections. HPB. 2000;2(3):333–339. doi:10.1016/S1365-182X(17)30755-4
   Google Scholar
• Yamamoto K, Imamura H, Matsuyama Y, et al. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol. 2010;45(12):1272–1282. doi:10.1007/s00535-010-0278-5
   PubMed Web of Science ®Google Scholar
• Feng H, Li B, Li Z, Wei Q, Ren L. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma. BMC Cancer. 2021;21(1):401. doi:10.1186/s12885-021-08138-3
   PubMed Web of Science ®Google Scholar
• Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347(3):168–174. doi:10.1056/NEJMoa013215
   PubMed Web of Science ®Google Scholar
• Yang HI, Yuen MF, Chan HL, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol. 2011;12(6):568–574. doi:10.1016/S1470-2045(11)70077-8
   PubMed Web of Science ®Google Scholar
• Yang HI, Sherman M, Su J, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol. 2010;28(14):2437–2444. doi:10.1200/JCO.2009.27.4456
   PubMed Web of Science ®Google Scholar
• Wang X, Liu X, Wang P, et al. Antiviral therapy reduces mortality in hepatocellular carcinoma patients with low-level hepatitis B viremia. J Hepatocell Carcinoma. 2021;8:1253–1267. doi:10.2147/JHC.S330301
   PubMed Web of Science ®Google Scholar
• He Z, Tang D. Perioperative predictors of outcome of hepatectomy for HBV-related hepatocellular carcinoma. Front Oncol. 2023;13:1230164. doi:10.3389/fonc.2023.1230164
   PubMed Web of Science ®Google Scholar
• Li P, Wang Y, Yu J, et al. Tenofovir vs Entecavir among patients with HBV-related HCC after resection. JAMA Network Open. 2023;6(10):e2340353. doi:10.1001/jamanetworkopen.2023.40353
   PubMed Web of Science ®Google Scholar
• Yin Y, Cheng JW, Chen FY, et al. A novel preoperative predictive model of 90-day mortality after liver resection for huge hepatocellular carcinoma. Ann Transl Med. 2021;9(9):774. doi:10.21037/atm-20-7842
   PubMed Web of Science ®Google Scholar
• Wang Z, Duan Y, Zhang J, et al. Preoperative antiviral therapy and microvascular invasion in hepatitis B virus-related hepatocellular carcinoma: a meta-analysis. Eur J Pharmacol. 2020;883:173382. doi:10.1016/j.ejphar.2020.173382
   PubMed Web of Science ®Google Scholar
• Huang S, Xia Y, Lei Z, et al. antiviral therapy inhibits viral reactivation and improves survival after repeat hepatectomy for hepatitis B virus-related recurrent hepatocellular carcinoma. J Am Coll Surg. 2017;224(3):283–293.e4. doi:10.1016/j.jamcollsurg.2016.11.009
   PubMed Web of Science ®Google Scholar
• Fu J, Ding Z, Chen Q, et al. Distinct impacts of pre-operative antiviral treatment on post-operative outcomes of HBV-related hepatocellular carcinoma: a landmark analysis. J Cancer. 2021;12(1):170–180. doi:10.7150/jca.47125
   PubMed Web of Science ®Google Scholar